Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral formulations containing metformin and alpha-glycosidase inhibitor, and preparation method thereof

A technology of metformin and compound preparations, which is applied in the direction of medical preparations containing active ingredients, pill delivery, pharmaceutical formulations, etc. It can solve the problems of metformin not being released quickly and the bioavailability of metformin decrease, so as to control blood sugar and increase adaptability Effect

Inactive Publication Date: 2013-06-12
CJ HEALTHCARE CORP
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, formulations containing metformin do not release metformin rapidly and then migrate to the lower part of the gastrointestinal tract over time, making metformin less bioavailable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral formulations containing metformin and alpha-glycosidase inhibitor, and preparation method thereof
  • Oral formulations containing metformin and alpha-glycosidase inhibitor, and preparation method thereof
  • Oral formulations containing metformin and alpha-glycosidase inhibitor, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: Preparation of metformin and voglibose compound preparation (1)

[0044] 300g of metformin hydrochloride and 36g of hydroxypropyl cellulose were uniformly mixed; sieved with a 20-mesh mesh; added to a fluidized bed granulator; and then preheated at 60°C for 10 minutes. 6 g of hydroxypropyl cellulose was dissolved in 120 mL of water to prepare a binding solution; the binding solution was sprayed at a rate of 7 mL per minute, thereby preparing primary granules; and the primary granules were then sieved using a 20-mesh mesh.

[0045] 0.18 g of voglibose and 6 g of hydroxypropyl cellulose were dissolved in 120 mL of water by thorough stirring, and then fully sprayed onto the granules prepared in the above manner to prepare secondary granules. Finish by sieving the secondary granules using a 20 mesh mesh, then drying.

Embodiment 2

[0046] Example 2: Preparation of metformin and voglibose compound preparation (2)

[0047] 300g of metformin hydrochloride and 36g of hydroxypropyl cellulose were uniformly mixed; sieved with a 20-mesh mesh; added to a fluidized bed granulator; and then preheated at 60°C for 10 minutes. 6 g of hydroxypropyl cellulose was dissolved in 120 mL of water to prepare a binding solution; the binding solution was sprayed at a rate of 7 mL per minute, thereby preparing primary granules; and the primary granules were then sieved using a 20-mesh mesh.

[0048] 0.12 g of voglibose and 6 g of hydroxypropyl cellulose were dissolved in 120 mL of water by thorough stirring, and then sprayed onto the granules prepared in the above manner to prepare secondary granules. Finish by sieving the secondary granules using a 20 mesh mesh, then drying.

Embodiment 3

[0049] Example 3: Preparation of metformin and voglibose compound preparation (3)

[0050] 300g of metformin hydrochloride and 36g of hydroxypropyl cellulose were uniformly mixed; sieved with a 20-mesh mesh; added to a fluidized bed granulator; and then preheated at 60°C for 10 minutes. 6 g of hydroxypropyl cellulose was dissolved in 120 mL of water to prepare a binding solution; the binding solution was sprayed at a rate of 7 mL per minute, thereby preparing primary granules; and the primary granules were then sieved using a 20-mesh mesh.

[0051] 0.36 g of voglibose and 6 g of hydroxypropyl cellulose were dissolved in 120 mL of water by thorough stirring, and then sprayed onto the granules prepared in the above manner to prepare secondary granules. Sieve the secondary granules through the use of a 20-mesh mesh, then dry and finish.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an oral formulation which contains a secondary wet granule produced by coating a primary wet granule with a mixed aqueous solution of an alpha-glycosidase inhibitor and hydroxypropyl cellulose, wherein said primary wet granule is produced by combining a mixed powder comprising metformin and hydroxypropyl cellulose with an aqueous solution of hydroxypropyl cellulose serving as a binding solution. In addition, the present invention provides a method for preparing an oral formulation, comprising the steps of: injecting the mixed powder of metformin and hydroxypropyl cellulose into a fluidized bed granulator, and spraying the aqueous solution of hydroxypropyl cellulose onto the mixed powder to produce a primary wet granule; and spraying the mixed aqueous solution of alpha-glycosidase inhibitor and hydroxypropyl cellulose onto the primary wet granule in the fluidized bed granulator to produce a secondary wet granule.

Description

technical field [0001] The present invention relates to an oral preparation comprising metformin and voglibose, wherein the oral preparation is used for treating type II diabetes, and a preparation method thereof. More specifically, the present invention relates to an oral formulation capable of improving medication compliance of patients because it is easy to take and has an effect equal to or greater than that of metformin and voglibose co-administered as separate formulations. Background technique [0002] Type 2 diabetes, non-insulin-dependent diabetes, is the most common metabolic disease, with a global prevalence of about 5%. In addition, it is estimated that from now to 2010, the prevalence of type II diabetes will rise steadily to 7%, and within 10 years from now, the total number of diabetic patients will increase to about double. [0003] The pathophysiology of type II diabetes is characterized by insulin secretory dysfunction and insulin resistance. Insulin resi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/155A61K47/38A61K9/16A61K9/20A61K9/48A61P3/10
CPCA61K9/167A61K31/155A61K45/06A61P3/10A61P43/00A61K2300/00A61K9/16
Inventor 赵日焕洪一基安泰军李镕宅郑善五尹明植权五亿李恃氾吴多苑崔洛铉李熙贞卢贤贞
Owner CJ HEALTHCARE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com